IDYA - Ideaya Biosciences Inc

IDYA - Ideaya Biosciences Inc

https://www.ideayabio.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

This Royal Caribbean Cruises Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - IDEAYA Biosciences ( NASDAQ:IDYA ) , Carnival ( NYSE:CCL )

Benzinga • 1 month, 3 weeks ago • score: 0.18

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Kevin Kopelman initiated coverage on Royal Caribbean Cruises Ltd.

This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Eupraxia Pharmaceuticals ( NASDAQ:EPRX ) , IDEAYA Biosciences ( NASDAQ:IDYA )

Benzinga • 2 months, 2 weeks ago • score: -0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Brandon Folkes initiated coverage on Eupraxia Pharmaceuticals Inc.

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences ( IDYA )

Zacks Commentary • 7 months ago • score: 0.14

The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...

IDEAYA Biosciences, Inc. ( IDYA ) Reports Q4 Loss

Zacks Commentary • 7 months ago • score: 0.14

IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About IDEAYA Biosciences ( IDYA ) Rating Upgrade to Buy

Zacks Commentary • 7 months ago • score: 0.31

IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.

52W High

$37.80

52W Low

$13.45

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.12

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

4.65

EV/EBITDA (<8 favorable)

-7.80

EV/Revenue (<3 favorable)

248.18

P/S (TTM) (<3 favorable)

340.06

P/B (<3 favorable)

2.48

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.91%

Institutions (25–75% balanced)

114.91%

Shares Outstanding

87,644,000

Float

81,816,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

7,000,000

Gross Profit (TTM)

-335,447,008

EPS (TTM)

-3.84

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-54.89%

ROE (TTM) (>15% strong)

-0.35%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.79

Momentum

Bearish momentum

Value

0.2962

Previous

0.3623

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025